The holiday season is all about joy, but how do you sustain that feeling throughout the year? Every culture has a brand that captures the state of happiness as much as its national aesthetic. In ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...

Orforglipron maintains weight loss after switching from injectable GLP-1 drugs Lilly and Novo Nordisk await U.S. regulatory approvals for weight-loss pills FDA may expedite review of Lilly's ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the company's lead in this niche of the industry. Even after their strong run, Lilly's ...

Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in nearby Lebanon, accounting for more than three-quarters of the 445 open positions the ...

Peter Arnett, the Pulitzer Prize-winning reporter who spent decades dodging bullets and bombs to bring the world eyewitness accounts of war from the rice paddies of Vietnam to the deserts of Iraq, has ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic and Paralympic Winter Games, the company is drawing parallels between what ...

What To Know: Novo Nordisk, one of Eli Lilly’s main competitors, announced a regulatory breakthrough for an oral weight loss drug. The FDA approved the company’s pill form of Wegovy, making it the ...

The obesity and diabetes drug boom is no longer a one-cycle story. Demand for GLP-1 treatments continues to exceed supply, with physicians expanding use beyond diabetes into weight management and ...

Aktis Oncology (AKTS), a radiopharmaceutical drug developer backed by pharma giants such as Eli Lilly (LLY), has filed its preliminary regulatory filings with the Securities and Exchange Commission ...